Adaptive Biotechnologies’ September 2022 agreement with healthcare investment firm OrbiMed was a royalty-financing deal, not a single unconditional $250 million payment. Contemporary reporting described $125 million initially, with additional tranches available under specified options or conditions, in exchange for a share of revenue. Adaptive said the capital would extend its cash runway and support growth in minimal residual disease (MRD) and immune medicine.
What Adaptive and OrbiMed agreed to
GeekWire reported on September 12, 2022, that Adaptive Biotechnologies had entered a royalty-financing agreement with OrbiMed. The reported headline figure was up to $250 million, but the structure comprised an initial tranche and potential additional funding—not one guaranteed payment of the full amount.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Biotechnology | $103.82 | Buy on Amazon |
| 2 |
|
Basic Laboratory Methods for Biotechnology: Textbook and Laboratory Reference | $95.33 | Buy on Amazon |
| 3 |
|
Introduction to Biotechnology, Global Edition | $70.00 | Buy on Amazon |
| 4 |
|
Biotechnology: The Technological Applications of Genetics and Genomics | $141.90 | Buy on Amazon |
| 5 |
|
Introduction to Biotechnology (What's New in Biology) | $242.64 | Buy on Amazon |
| Reported tranche | Amount | Reported revenue share to OrbiMed |
|---|---|---|
| Initial tranche | $125 million | 5% of GAAP revenue |
| Second tranche | Optional additional $75 million | 8% of GAAP revenue |
| Third tranche | Access to a further $50 million for potential mergers and acquisitions | 10% of GAAP revenue |
These tranche amounts and revenue-share percentages were reported by GeekWire at the time of the deal. A later annual-report search extract confirms that Adaptive entered a purchase agreement with OrbiMed in September 2022, but does not independently confirm those specific tranche economics. The reported percentages rise with each tranche; they should not be read as a single rate applying to all funding.
How the financing worked
In a royalty financing, a company receives capital and agrees to pay the investor a defined portion of revenue. Unlike issuing shares, that structure does not itself require selling equity. The trade-off is that revenue participation can reduce the company’s share of future receipts. Here, GeekWire’s account describes the revenue share as increasing from 5% to 8% and then 10% as further tranches were involved.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →#1 Best Overall
The later annual-report extract adds an important qualification: Adaptive granted OrbiMed a security interest in core platform technology assets, subject to customary exclusions. That indicates a secured-credit dimension alongside the reported royalty economics. The accessible extract does not establish the full collateral definitions, repayment mechanics, covenants, maturity, or what obligations may remain today.
Why Adaptive said it wanted the capital
Adaptive CEO and co-founder Chad Robins said the arrangement was intended to extend the company’s cash runway and give it flexibility to invest in growth in MRD and immune medicine. GeekWire also reproduced Robins’ statement: “We are excited to work with OrbiMed on this creative royalty structure to continue unlocking the full potential of our immune medicine platform”.
OrbiMed general partner Matthew Rizzo described the investment as reflecting confidence in Adaptive and the potential of its immune-medicine platform. That was OrbiMed’s stated view, not independent evidence that the deal’s economics were favorable to Adaptive.
What Adaptive’s finances looked like at the time
The figures below are historical context from Adaptive’s second quarter of 2022 and its 2022 outlook, as reported by GeekWire on September 12, 2022. They are not current financial figures.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Rank #3
- Adaptive reported $450 million in cash and marketable securities at the end of Q2 2022.
- Q2 2022 revenue was $43.7 million, up 13% year over year; operating expenses were $96.2 million, and the company recorded a $52.1 million net loss.
- clonoSEQ test volume grew 53% year over year and 17% sequentially in Q2 2022.
- The company’s then-current 2022 outlook was revenue of $185 million to $195 million and operating expenses of $410 million to $415 million.
The cash balance and quarterly loss help explain management’s stated interest in runway, but those figures alone do not establish insolvency, imminent distress, or that this was the only financing route available. GeekWire also reported that Adaptive had refocused on MRD and immune medicine in May 2022.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the deal does—and does not—tell investors
The agreement shows one way a company can seek capital without issuing equity: trade a portion of future revenue and grant security interests. For Adaptive, the reported structure paired an initial $125 million with access to possible further funding and higher revenue-share rates for later tranches. The practical cost therefore depended in part on whether additional tranches were used and on the revenue share attached to them.
The public details cited here do not establish how much Adaptive ultimately drew, whether later amendments or waivers occurred, how much it has paid, or whether any obligation remains outstanding. The September 2022 announcement should not be used as a description of Adaptive’s current balance sheet.
Quick Recap
Sources
- GeekWire, September 12, 2022: Adaptive Biotechnologies inks deal with healthcare fund to beef up balance sheet
- Adaptive Biotechnologies SEC filings index
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
